19 Oct 2020 Henlius and Essex Enter into a Global Co-Development and Exclusive License Agreement, to Jointly Develop Bevacizumab to Treat Ophthalmic Diseases
17 Oct 2020 Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
17 Oct 2020 Janssen Receives CHMP Positive Opinion for Expanded Use of TREMFYA®▼ (guselkumab) in the Treatment of Active Psoriatic Arthritis (PsA) in the European Union (EU)
17 Oct 2020 Merck Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308) in Combination With KEYTRUDA in Advanced Non Small Cell Lung Cancer
16 Oct 2020 CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
15 Oct 2020 Lilly Statement on the NIAID Decision to Pause Enrollment in ACTIV-3 Clinical Trial
15 Oct 2020 FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
15 Oct 2020 Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb®) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)
14 Oct 2020 Celltrion Initiates Post-exposure Prophylaxis Clinical Trial of an Anti-COVID-19 Monoclonal Antibody Treatment Candidate, CT-P59
13 Oct 2020 AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
13 Oct 2020 Dupixent® (dupilumab) Significantly Reduced Severe Asthma Attacks in Children and is the Only Biologic to Demonstrate Improvement in Children's Lung Function in a Randomized Phase 3 Trial
13 Oct 2020 Iksuda Therapeutics enters license agreement with University of Goettingen to develop a new generation of antibody drug conjugates
12 Oct 2020 Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS® (ravulizumab-cwvz) with Significantly Reduced Infusion Time
10 Oct 2020 Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA® (Rituximab Injection) in China
10 Oct 2020 COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442 rapidly advances into Phase III clinical trials
09 Oct 2020 First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine
07 Oct 2020 Opdivo (nivolumab) Plus Chemotherapy Shows Statistically Significant Improvement in Pathologic Complete Response as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
06 Oct 2020 Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis
06 Oct 2020 Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma
06 Oct 2020 Affimed Announces Dosing of First Patient in Phase 1 Clinical Trial of Cord Blood-derived Natural Killer Cells in Combination with the Innate Cell Engager AFM13
06 Oct 2020 Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)
06 Oct 2020 Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis
06 Oct 2020 Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
06 Oct 2020 Kodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion
06 Oct 2020 ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up